Genotype-related Effects of PUFA
Response to PUFA Intervention According to PPAR Genotypes
1 other identifier
interventional
200
0 countries
N/A
Brief Summary
To assess the bioefficacy of omega-3 fatty acids (provided by intake of fish oil supplements) depending on genotype of relevant factors in lipid metabolism
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable healthy
Started Jun 2012
Longer than P75 for not_applicable healthy
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 12, 2014
CompletedFirst Posted
Study publicly available on registry
November 20, 2014
CompletedNovember 20, 2014
November 1, 2014
1.9 years
November 12, 2014
November 17, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in triglyceride levels in plasma
Baseline and 6 weeks intervention
Secondary Outcomes (1)
Assess bioefficacy of EPA and DHA supplementation
Baseline and 6 weeks intervention
Study Arms (1)
Supplementation
EXPERIMENTALSupplementation
Interventions
Eligibility Criteria
You may qualify if:
- Healthy adult between 18 and 40 years of age
- BMI between 18.5 and 30 kg/m2
- Sedentary to moderate physical activity habits
You may not qualify if:
- Concomitant treatment: Consumption of dietary supplements or any medication that can affect the study outcomes
- Actively smoking
- Suspected abuse of alcohol or illicit drugs
- Significant illness within the two weeks prior to study start or any active systemic infection or medical condition that may require treatment during the study
- Known or suspected medical condition related to coagulation
- Subject who cannot be expected to comply with the study procedures
- Currently participating or having participated in another clinical trial during the last 4 weeks prior to beginning of this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Binia A, Vargas-Martinez C, Ancira-Moreno M, Gosoniu LM, Montoliu I, Gamez-Valdez E, Soria-Contreras DC, Angeles-Quezada A, Gonzalez-Alberto R, Fernandez S, Martinez-Conde D, Hernandez-Moran B, Ramirez-Solano M, Perez-Ortega C, Rodriguez-Carmona Y, Castan I, Rubio-Aliaga I, Vadillo-Ortega F, Marquez-Velasco R, Bojalil R, Lopez-Alvarenga JC, Valet P, Kussmann M, Silva-Zolezzi I, Tejero ME. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARalpha L162V and PPARgamma2 P12A. J Nutr Biochem. 2017 May;43:98-106. doi: 10.1016/j.jnutbio.2017.02.002. Epub 2017 Feb 10.
PMID: 28282585DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Maria Elizabeth Tejero Barrera, PhD
Instituto Nacional de Medicina Genomica
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 12, 2014
First Posted
November 20, 2014
Study Start
June 1, 2012
Primary Completion
May 1, 2014
Study Completion
August 1, 2014
Last Updated
November 20, 2014
Record last verified: 2014-11